Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Oncolytics Biotech Inc ONCY


Primary Symbol: T.ONC

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune... see more

Bullboard (TSX:ONC)

View:
Comment by Noteableon Jun 08, 2024 11:59am

RE:CD8+ TiLs and T-cell exhaustion

" Patients with early-stage triple-negative breast cancer (TNBC) who had breast tissue with more tumor-infiltrating lymphocytes (TIL) and did not receive adjuvant or neoadjuvant chemotherapy ...more  
Comment by Noteableon Jun 08, 2024 11:49am

RE:ONCY's pelareorep can provide a fine T-cell boost for ADCs

Challenges Faced by Antibody-Drug Conjugates Potential cancer resistance to ADCs Cancer cells can gradually develop mechanisms to resist ADCs, reducing their effectiveness over time. This ...more  
Comment by Peladawnon Jun 08, 2024 11:37am

RE:RE:RE:I agree 109%….

Casey....check out Bucky's posting history....he's been posting since the mid 2022s, claiming that he's been a very large shareholder since about 2019, and he has done nothing but mock and ...more  
Comment by CaseyLon Jun 08, 2024 10:44am

RE:RE:I agree 109%….

You doubt a significant bought deal would happen?
Comment by Buckhenryon Jun 07, 2024 3:04pm

RE:RE:I agree 109%….

Pumpers been speculating on a buyout and price since god was a kid. 
Comment by fasttrack5on Jun 07, 2024 3:02pm

RE:I agree 109%….

Exactly CF and as stated previously a partnership or complete buyout is what I'm waiting on. Sooner the better for shareholders. Shazam would be this quarter or latest 3rd qrt. just sayin:) RJ
Post by canadafanon Jun 07, 2024 2:10pm

I agree 109%….

It was stated in short message....something I'm ni5 good at lol. recappjng the points. they are waiting & expecting FDA type c meeting date/ follow up etc.....very soon. the first patient to ...more  
Comment by Noteableon Jun 07, 2024 12:08pm

RE:RE:RE:RE:RE:RE:RE:RE:ONCY's pelareorep can provide a fine T-cell boost for ADCs

ImmuoGen's only approval occurred as an Accelerated Approval in November 2022. Their follow-on confirmatory trial is  MIRASOL: Monotherapy in FRα-High Platinum-Resistant Ovarian Cancer ...more  
Comment by Noteableon Jun 07, 2024 12:00pm

RE:RE:RE:RE:RE:RE:RE:ONCY's pelareorep can provide a fine T-cell boost for ADCs

ImmuoGen's only approval occurred in November 2022, for the treatment of adult patients with folate receptor-alpha (FRα) positive, platinumresistant epithelial ovarian, fallopian tube, or primary ...more  
Comment by inthnoon Jun 07, 2024 11:23am

RE:RE:RE:RE:RE:RE:RE:ONCY's pelareorep can provide a fine T-cell boost for ADCs

Doing comparisons it would be nice if onc is being considered for a BO as opposed to a partnership as it ends all uncertainty surrounding the company. As to IMmunoGEn, I believe that they were worth ...more  
Comment by Noteableon Jun 07, 2024 10:58am

RE:RE:RE:RE:RE:RE:ONCY's pelareorep can provide a fine T-cell boost for ADCs

 ImmunoGen has been around for 40 years ... before being acquired by Abbive this year for US$10.1 Billion.
Comment by Noteableon Jun 07, 2024 10:23am

RE:RE:RE:RE:RE:ONCY's pelareorep can provide a fine T-cell boost for ADCs

In February 2024, AbbVie closed a $10.1 billion deal acquiring ImmunoGen, an ADC-focused biotechnology company headquartered in suburban Boston.  June 07, 2024 - Abbive reported on the  ...more  
Comment by Noteableon Jun 07, 2024 10:16am

RE:RE:RE:RE:RE:Panc Biomarker Presentation at ASCO GI 18-20 Jan 2024

“The data from [ the Goblet Phase 2 PDAC Cohort study showed ] a correlation between the expansion of TIL-specific clones and tumor response, which provides compelling support for the use of ...more  
Comment by Noteableon Jun 07, 2024 9:24am

RE:RE:RE:RE:Very I last few weeks, months

These are the nattering nancies of negativity who think that their irrationality is somehow funny.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities